A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
Katharina A. Mayer(Medical University of Vienna), Georg A. Böhmig(Medical University of Vienna), Rainer Boxhammer(Medical University of Vienna), Bilgin Osmanodja(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Eva Schrezenmeier(Leibniz Association), Hannes Vietzen(Medical University of Vienna), Susanne Haindl(Medical University of Vienna), Johannes Kläger(Medical University of Vienna), Christa Firbas(Medical University of Vienna), Jaideep S. Dudani(Medical University of Vienna), Klemens Budde(Charité - Universitätsmedizin Berlin), Heinz Regele(University of Vienna), Konstantin Doberer(Medical University of Vienna), Farsad Eskandary(Medical University of Vienna), Bernd Jilma(Medical University of Vienna), Uptal D. Patel(Medical University of Vienna), Fabian Halleck(Charité - Universitätsmedizin Berlin), Elisabeth Puchhammer-Stöckl(Medical University of Vienna), Julia Beck(Medical University of Vienna), Ekkehard Schütz(Medical University of Vienna), Aylin Akifova(Medical University of Vienna), Houston N Gilbert(Medical University of Vienna), Matthias Diebold(Medical University of Vienna), Philip F Halloran(Medical University of Vienna), Martina Schatzl(Medical University of Vienna), Sabine Schranz(Medical University of Vienna), Silke Kasbohm(Medical University of Vienna), Alexander Kainz(Medical University of Vienna), Kerstin Amann(Medical University of Vienna), Nicolas Kozakowski(Medical University of Vienna)
Cited by 151
Related Papers
Banff 07 Classification of Renal Allograft Pathology: Updates and Future Directions
|American Journal of Transplantation|2008|1.9k
Antibody-Mediated Rejection Criteria - an Addition to the Banff ’97 Classification of Renal Allograft Rejection
|American Journal of Transplantation|2003|1.1k
The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection
|American Journal of Transplantation|2020|809
Banff ’09 Meeting Report: Antibody Mediated Graft Deterioration and Implementation of Banff Working Groups
|American Journal of Transplantation|2010|760
Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
|New England Journal of Medicine|2010|574